

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Buervenich, et al.
 Serial No. : 10/019,385
 Filing or 371(c) Date : April 25, 2002
 For : MUTATED NURR1 GENE
 Examiner : C. Qian
 Group Art Unit : 1636

"Express Mail" Label No. **EF 173120333 US**
Date of Deposit March 16, 2006
 I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the:
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450
BERNARD MAYS
Bernard Mays
 (Signature of person mailing paper or fee)

Mail Stop PCT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION TO COMPLY

Sir:

This is in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed January 19, 2006. As required, a copy of the Notification is provided herewith.

In response to the Notification, Applicants provide herewith the following:

- 1) An initial computer readable form (CRF) of the Sequence Listing;
- 2) An initial paper copy of the Sequence Listing;
- 3) An amendment specifically directing entry of the paper copy into the application;
- 4) A statement attesting to the identity of the information in the CRF and paper copy of the Sequence Listing; and
- 5) A statement that no new matter has been introduced.

The Office issued a Notice of Acceptance of Application on June 6, 2002. Applicants note that it took the Office more than three and one-half years to withdraw that Notice and issue the Notification to which this is a reply. Applicants respectfully request that, particularly in view of this lengthy delay, completion of the initial processing of the application be expedited and the application be passed on to the Examiner immediately thereafter for substantive examination.

No fees should be due in connection with this communication. However, should it be determined that a fee is required for any reason, the Commissioner is hereby authorized to charge it to Deposit Account No. 23-1703.

Dated: March 16, 2006

Respectfully submitted,



Richard J. Sterner
Reg. No. 35,372

Customer No. 007470
(212) 819-8200

Agent's Direct Line:
(212) 819-8783

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/019,385	Silvia Buervenich	11003326-0677

007470
WHITE & CASE LLP
PATENT DEPARTMENT
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

WHITE & CASE LLP
PATENT DEPARTMENT

INTERNATIONAL APPLICATION NO.	
PCT/SE00/01380	
I.A. FILING DATE	PRIORITY DATE
06/29/2000	06/30/1999

CONFIRMATION NO. 1420

371 FORMALITIES LETTER



OC000000017875859

JAN 22 2006

Date Mailed: 01/19/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ patent@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/019,385	PCT/SE00/01380	11003326-0677

FORM PCT/DO/EO/922 (371 Formalities Notice)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Buervenich, et al.
Serial No. : 10/019,385
Filing or 371(c) Date : April 25, 2002
For : MUTATED NURR1 GENE
Examiner : C. Qian
Group Art Unit : 1636

"Express Mail" Label No. **EF 173120333 US**

Date of Deposit March 16, 2006

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BERNARD MAYS

Bernard Mays

(Signature of person mailing paper or fee)

Mail Stop PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF REVISED DRAWINGS

Sir:

It is requested that the revised versions of Figures 1 and 2 presented herewith on two separate drawing sheets be entered as replacements for Figures 1 and 2 as submitted with the original application.

It has come to the attention of Applicants that the first of the two original drawing sheets submitted with the application contains a version of Figure 1 and the second sheet contains both a version of Figure 1 and of Figure 2. In order to avoid repetition and confusion, Figures 1 and 2 are presented on separate drawing sheets provided herewith.

Figure 1 contains sequence disclosure of portions of exon 3 of the Nurrl gene. This disclosure is part of the Sequence Listing being presented concurrently herewith under the same cover in response to the January 19, 2006 Notice to Comply. Figure 1 has been amended to identify the sequences found therein by their identification numbers as found in the Sequence Listing.

No new matter has been introduced by the revised figures presented herein. The revised drawing sheets comply in every way with the requirements of 37 C.F.R. §1.84. Entry of the revised drawing sheets is respectfully requested.

No fees should be due in connection with this communication. However, should it be determined that a fee is required for any reason, the Commissioner is hereby authorized to charge it to Deposit Account No. 23-1703.

Dated: March 16, 2006

Respectfully submitted,



Richard J. Sterner
Reg. No. 35,372

Customer No. 007470
(212) 819-8200

Agent's Direct Line:
(212) 819-8783

Enclosures